Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients
Cancer and Metastasis Reviews · 2025
DOI: 10.1007/s10555-025-10299-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer and Metastasis Reviews, 2025. Verfasst von Prathvi V Shenoy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India. Hauptthemen laut MEDLINE: Gefitinib, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Manipal Academy of Higher Education, Manipal.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Gefitinib is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of non-small cell lung cancer (NSCLC). It is metabolized extensively in the liver by enzymes encoded by CYP3A4 , CYP2D6, and CYP3A5 and is the substrate of membrane transporters including ABCB1 and ABCG2 . Evidence shows that single-nucleotide polymorphisms (SNPs) in these metabolizing and transporting genes contribute to the inter-individual variability in gefitinib response and development of gefitinib-induced adverse drug reactions (ADRs). This narrative review identifies the existing literature exploring the impact of SNPs on plasma gefitinib concentration and ADRs in patients with NSCLC receiving gefitinib therapy. SNPs were identified in drug-metabolizing enzyme coding genes, including CYP3A4, CYP2D6, CYP3A5, and other CYP homologs, drug transporters including ABCB1, ABCG2, SLCO1B1 and other genes, including UGT1A7 and FOXO3. Current research has not identified any genetic association between specific SNPs in ABCB1, OATP1B1, and UGT1A7 and the pharmacokinetics of gefitinib. Additionally, most of these studies focused on individual SNP associations; however, it may be more important to consider them in combination to better understand their collective impact on gefitinib ADR. Hence, further comprehensive research is essential to examine these genetic variants across different ethnic groups, monitor the drug-drug interactions, and study the phenoconversion to draw definitive conclusions about the pharmacokinetics of gefitinib. This could lead to the development and implementation of a genotyping-based approach for gefitinib dosage optimization in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
- Department of Medical Genetics, Kasturba Medical College Manipal, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
- Department of Medical Oncology, Kasturba Medical College Manipal, Manipal Comprehensive Cancer Care Centre, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
- Department of Translational Medicine, All India Institute of Medical Sciences, Bhopal, 462020, Madhya Pradesh, India.
- Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.
- Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India. mahadev.rao@manipal.edu.
ORCID-Profile: Prathvi V Shenoy, Rama Rao Damerla, Sharada Mailankody
Förderung
- Manipal Academy of Higher Education, Manipal
Zitieren
APA
Shenoy, P. V., Baburaj, G., Damerla, R. R., Pai, A., Mailankody, S., Munisamy, M., Mallayasamy, S., Udupa, K. S., Kolesar, J., & Rao, M. (2025). Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-025-10299-7
Vancouver
Shenoy PV, Baburaj G, Damerla RR, Pai A, Mailankody S, Munisamy M, et al. Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients. Cancer and Metastasis Reviews. 2025. doi:10.1007/s10555-025-10299-7
BibTeX
@article{Shenoy2025,
author = {Shenoy, Prathvi V and Baburaj, Gayathri and Damerla, Rama Rao and Pai, Ananth and Mailankody, Sharada and Munisamy, Murali and Mallayasamy, Surulivelrajan and Udupa, Karthik S and Kolesar, Jill and Rao, Mahadev},
title = {Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients},
journal = {Cancer and Metastasis Reviews},
year = {2025},
doi = {10.1007/s10555-025-10299-7}
}
EUVIMED